Raymond James Financial Inc. upgraded Incyte Corporation (NASDAQ:INCY) to Outperform in a report released today.
- Updated: September 29, 2016
Raymond James Financial Inc. has upgraded Incyte Corporation (NASDAQ:INCY) to Outperform in a report released on 9/29/2016.
Boasting a price of $93.20, Incyte Corporation (NASDAQ:INCY) traded 4.64% higher on the day. With the last stock price close up 17.20% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Incyte Corporation has recorded a 50-day average of $82.31 and a two hundred day average of $79.52. Volume of trade was up over the average, with 2,653,106 shares of INCY changing hands over the typical 1,159,020
With a total market value of $0, Incyte Corporation has price-earnings ratio of 253.26 with a one year low of $55.00 and a one year high of $131.33 .
A total of 14 equity analysts have released a ratings update on INCY. Seven equity analysts rating the company a strong buy, eight equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $91.36.
Brief Synopsis About Incyte Corporation (NASDAQ:INCY)
Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.